frovatriptan Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
serotonin (5-HT1) receptor agonists, sumatriptan derivatives 1251 158747-02-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • frovatriptan
  • (R)-Frovatriptan
  • frovatriptan succinate
  • frovatriptan succinate hydrate
  • SB 209509
  • VML251
  • Molecular weight: 243.31
  • Formula: C14H17N3O
  • CLOGP: 0.72
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 3
  • TPSA: 70.91
  • ALOGS: -3.30
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2.50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 6 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.44 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 27 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 3.60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.85 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 24 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 8, 2001 FDA ENDO PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Migraine 109.86 29.53 45 970 69981 46615066
Lichen planus 56.60 29.53 12 1003 1821 46683226
Headache 34.97 29.53 47 968 478305 46206742

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
ATC N02CC07 NERVOUS SYSTEM
ANALGESICS
ANTIMIGRAINE PREPARATIONS
Selective serotonin (5HT1) agonists
FDA MoA N0000175763 Serotonin 1b Receptor Agonists
FDA MoA N0000175764 Serotonin 1d Receptor Agonists
FDA EPC N0000175765 Serotonin-1b and Serotonin-1d Receptor Agonist
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018490 Serotonin Agents
MeSH PA D017366 Serotonin Receptor Agonists

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Migraine indication 37796009 DOID:6364
Hypercholesterolemia contraindication 13644009
Coronary artery spasm contraindication 23687008 DOID:11840
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Hemiplegic migraine contraindication 59292006
Diabetes mellitus contraindication 73211009 DOID:9351
Vascular insufficiency of intestine contraindication 82196007
Prinzmetal angina contraindication 87343002
Angina pectoris contraindication 194828000
Cerebrovascular accident contraindication 230690007
Transient ischemic attack contraindication 266257000 DOID:224
Raynaud's phenomenon contraindication 266261006
Serotonin syndrome contraindication 371089000
Cardiovascular event risk contraindication 395112001
Peripheral vascular disease contraindication 400047006
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Hypertensive urgency contraindication 443482000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.14 acidic
pKa2 12.79 acidic
pKa3 10.16 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 1B GPCR AGONIST Ki 7.99 CHEMBL CHEMBL
5-hydroxytryptamine receptor 1D GPCR AGONIST Ki 8.36 CHEMBL CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 7.21 CHEMBL

External reference:

IDSource
4021297 VUID
N0000148734 NUI
D04264 KEGG_DRUG
158930-17-7 SECONDARY_CAS_RN
4021297 VANDF
C0754647 UMLSCUI
CHEBI:134991 CHEBI
CHEMBL1279 ChEMBL_ID
CHEMBL2138684 ChEMBL_ID
CHEMBL1200371 ChEMBL_ID
DB00998 DRUGBANK_ID
C108128 MESH_SUPPLEMENTAL_RECORD_UI
7191 IUPHAR_LIGAND_ID
7661 INN_ID
H82Q2D5WA7 UNII
77992 PUBCHEM_CID
228783 RXNORM
16207 MMSL
239641 MMSL
d04776 MMSL
009509 NDDF
009510 NDDF
370214004 SNOMEDCT_US
411990007 SNOMEDCT_US
767324002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Frovatriptan HUMAN PRESCRIPTION DRUG LABEL 1 0378-3140 TABLET, FILM COATED 2.50 mg ORAL ANDA 26 sections
Frovatriptan Succinate HUMAN PRESCRIPTION DRUG LABEL 1 0603-3718 TABLET, FILM COATED 2.50 mg ORAL NDA 25 sections
FROVA HUMAN PRESCRIPTION DRUG LABEL 1 16590-396 TABLET, FILM COATED 2.50 mg ORAL NDA 25 sections
FROVA HUMAN PRESCRIPTION DRUG LABEL 1 63481-025 TABLET, FILM COATED 2.50 mg ORAL NDA 25 sections
frovatriptan succinate HUMAN PRESCRIPTION DRUG LABEL 1 68462-694 TABLET, FILM COATED 2.50 mg ORAL ANDA 25 sections
Frovatriptan HUMAN PRESCRIPTION DRUG LABEL 1 69238-1539 TABLET, FILM COATED 2.50 mg ORAL ANDA 25 sections